

**AVL Medical Instruments UK Limited**

**Directors' report and financial  
statements**

Registered number 02425430

31 December 2018

WEDNESDAY



\*A85IY00X\*

A08

15/05/2019

#393

COMPANIES HOUSE

## Contents

Directors' report	1
Balance sheet	2
Notes to the financial statements	3

## Directors' report

The directors present their report together with the financial statements for the year ended 31 December 2018.

### Principal activities

The Company did not trade during the year to 31 December 2018. As such, the directors do not consider there to be any significant risks or uncertainties facing the Company. The Company is a limited liability company incorporated and domiciled in the United Kingdom. The address of the registered office is Charles Avenue, Burgess Hill, West Sussex, RH15 9RY.

### Business review

The results for the year to 31 December 2018 and the financial position of the Company as at that date are shown in the annexed financial statements. The Company has been dormant since 1 August 2000. The Company's assets and liabilities were sold to Roche Diagnostics Limited on 1 August 2000 and since that date the Company has not traded.

### Proposed dividend

No dividend payments were made during the year ended 31 December 2018 (2017: £Nil). The directors do not recommend the payment of a dividend.

### Directors and directors' interests

The directors who held office during the year were as follows:

Mr. R Fischer  
Mr. G Twist

### Political contributions

The Company made no political contributions during the year (2017: £Nil).

### Auditors

The directors have relied upon the provisions of Sections 480 and 476 of the Companies Act 2006 and have resolved not to appoint auditors.

By order of the board



**Geoffrey Twist**  
Managing Director UK & Ireland and Head of  
Management Centre European Agents

AVL Medical Instruments UK Limited  
Charles Avenue  
Burgess Hill  
West Sussex, RH15 9RY

10 May 2019

Company registration number 02425430

**Balance sheet**  
**at 31 December 2018**

	Note	2018 £	2017 £
<b>ASSETS</b>			
<b>Total assets</b>		-	-
<b>EQUITY AND LIABILITIES</b>			
<b>Equity attributable to the owners of the Company</b>			
Share capital	4.	19,304	19,304
Capital reserve		450,000	450,000
Retained earnings		(2,026,248)	(2,026,248)
<b>Total equity</b>		<b>(1,556,944)</b>	<b>(1,556,944)</b>
<b>Current liabilities</b>			
Other payables	3	1,556,944	1,556,944
<b>Total equity and liabilities</b>		-	-

The balance sheet should be read in conjunction with the notes to the financial statements.

For the year ending 31 December 2017 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Director's responsibilities;

- The members have not required the Company to obtain an audit of its accounts for the year in question in accordance with section 476,
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts

These financial statements were approved by the board of directors on 10 May 2019 and were signed on its behalf by:



**Geoffrey Twist**  
Managing Director UK & Ireland and Head of  
Management Centre European Agents

## Notes to the financial statements (forming part of the financial statements)

### 1 Accounting policies

AVL Medical Instruments Limited (the "Company") is a company incorporated in the UK.

The Company has not prepared an income statement or cash flow statement as there was no revenue during the year ended 31 December 2018, any expenses incurred by the Company have been borne by the shareholders.

### 2 Directors emoluments

The directors do not receive any remuneration in respect of their responsibilities as directors to the Company.

### 3 Other payables

	2018 £	2017 £
	<u>          </u>	<u>          </u>
Amounts due to group undertakings	<b>1,556,944</b>	1,556,944
	<u>          </u>	<u>          </u>

Included within other payables is £Nil (2017: £Nil) expected to be paid in more than 12 months.

### 4 Capital and reserves

The aggregate current and deferred tax relating to items that are charged or credited to equity is £Nil (2017: £Nil).

### 5 Share capital

Ordinary shares	2018	2017
	<u>          </u>	<u>          </u>
On issue at 1 January	<b>50,000</b>	50,000
	<u>          </u>	<u>          </u>
On issue at 31 December – fully paid	<b>50,000</b>	50,000
	<u>          </u>	<u>          </u>
	£	£
Allotted, called up and fully paid		
50,000 ordinary shares of 1 Swiss franc each	<b>19,304</b>	19,304
	<u>          </u>	<u>          </u>

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the Company. No dividends have been declared or paid in respect of the year ended 31 December 2018 (2017: £Nil).

## **Notes (continued)**

### **6 Ultimate parent company and parent company of larger group**

The Company is a subsidiary undertaking of Roche Holding Limited which is the ultimate parent company incorporated in Switzerland. The ultimate controlling party is also Roche Holding Limited whose address is Grenzacherstrasse 124, 4070 Basel, Switzerland.

The largest and smallest group in which the results of the Company are incorporated is that headed by Roche Holding Limited, a company incorporated in Switzerland. The consolidated financial statements of the group are available to the public and may be obtained from the Company Secretary, Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW.